Rifampicin-d3
(Synonyms: 利福平 d3) 目录号 : GC48048
An internal standard for the quantification of rifampicin
Cas No.:1262052-36-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Rifampicin-d3 is intended for use as an internal standard for the quantification of rifampicin by GC- or LC-MS. Rifampicin is a rifamycin antibiotic and inhibitor of bacterial RNA polymerase (IC50 = 0.01 μg/ml for the E. coli enzyme).1 It inhibits the growth of M. tuberculosis H37Rv in mouse peritoneal macrophages (MIC = 0.8 μg/ml) as well as clinical isolates of various species of Staphylococcus, Streptococcus, Haemophilus, and Neisseria (MICs = 0.009-1.4 μg/ml).2,3 Rifampicin increases survival in a mouse model of tuberculosis infection.3 It is also an agonist of the human pregnane X receptor (PXR; EC50 = ~2 μM).4 Formulations containing rifampicin have been used in the treatment of tuberculosis and meningococcal carriers.
1.Wehrli, W.Rifampin: Mechanisms of action and resistanceRev.Infect.Dis.5(3)S407-S411(1983) 2.Jhamb, S.S., Goyal, A., and Singh, P.P.Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460Braz. J. Infect. Dis.18(3)336-340(2014) 3.Arioli, V., Berti, M., Carniti, G., et al.Antibacterial activity of DL 473, a new semisynthetic rifamycin derivativeJ. Antibiot. (Tokyo)34(8)1026-1032(1981) 4.Gill, S.K., Xu, H., Kirchhoff, P.D., et al.Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerasesJournal of Medicinal Chemistry55(8)3814-3826(2012)
| Cas No. | 1262052-36-7 | SDF | |
| 别名 | 利福平 d3 | ||
| Canonical SMILES | OC1=C2C(C(O)=C(C)C(O[C@]3(C)O/C=C/[C@H](OC)[C@H](C)[C@]([C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)/C(N4)=O)(OC(C)=O)[H])=C2C3=O)=C(O)C4=C1/C=N/N5CCN(C([2H])([2H])[2H])CC5 | ||
| 分子式 | C43H55D3N4O12 | 分子量 | 826 |
| 溶解度 | Chloroform: slightly soluble,Methanol: slightly soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2107 mL | 6.0533 mL | 12.1065 mL |
| 5 mM | 0.2421 mL | 1.2107 mL | 2.4213 mL |
| 10 mM | 0.1211 mL | 0.6053 mL | 1.2107 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet